Johnson & Johnson's stock dropped 5% after reporting a 95.9% fall in net earnings caused by one-time charges including talc litigation costs, despite raising its full-year sales and adjusted earnings outlook. The company's Innovative Medicine division drove growth, while its MedTech division lagged, contributing to investor concerns. Management remains optimistic about long-term double-digit growth and a resolution to talc litigation, but near-term volatility may continue until MedTech performance improves and the talc issue is settled. Eli Lilly and Pfizer saw smaller declines, partly due to lack of exposure to medical devices.
Johnson & Johnson shares fell sharply by 5.96% to USD 248.00 on Pluang as of Oct 13, 2026 23:02 WIB, moving closer to their 52-week low of USD 186.00 and well below the 52-week high of USD 278.43. In contrast, Eli Lilly and Pfizer experienced much smaller declines of 0.65% and 0.32%, trading near their respective 52-week highs of USD 1.28K and USD 29.02. Investor activity on Pluang shows a strong sell sentiment for JNJ at 84%, compared to 71% for LLY and a more balanced 44% for PFE.
Johnson & Johnson reported a 6% revenue increase to $25.4 billion in Q3 2026, but earnings per share (EPS) declined 7.5% year-on-year, causing the stock to fall 5%. The company set aside $5.5 billion to resolve talc litigation, aiming for 95% plainti...
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
Johnson & Johnson increased its 2026 sales forecast to $101.2 billion and raised adjusted EPS guidance to $11.10 after reporting a 6% operational sales growth in Q3. The growth was driven by strong performance in its Innovative Medicine division, esp...
Johnson & Johnson's TREMFYA (guselkumab) demonstrated consistent combined fistula remission rates of up to 28% at Week 24 in adults with Crohn's disease and perianal fistula, outperforming placebo at 10%. New Phase 3 subgroup analyses from the FUZION...
Johnson & Johnson announced three-year data from Phase 3 GALAXI 2 and 3 studies showing TREMFYA (guselkumab) provides durable clinical remission rates up to 94% and endoscopic remission up to 61% in adults with moderately to severely active Crohn's d...
